A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1
| Autor: | N. C Tassopoulos, D. Tsantoulas, M. Raptopoulou, T. Vassiliadis, S. Kanatakis, E. Paraskevas, I. Vafiadis, A. Avgerinos, C. Tzathas, S. Manolakopoulos, I. Ketikoglou, P. Aggelis, K. Goritsas, G. Giannoulis, G. Hatzis G, K. Thomopoulos, E. Akriviadis, V. Sypsa, A. Hatzakis |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Hepacivirus Alpha interferon Interferon alpha-2 Gastroenterology Antiviral Agents law.invention chemistry.chemical_compound Randomized controlled trial law Interferon Virology Internal medicine Genotype Ribavirin medicine Humans Interferon alfa Aged Hepatology biology business.industry Interferon-alpha Hepatitis C Chronic Middle Aged biology.organism_classification Recombinant Proteins Regimen Infectious Diseases Treatment Outcome chemistry Immunology RNA Viral Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Journal of viral hepatitis. 10(3) |
| ISSN: | 1352-0504 |
| Popis: | SUMMARY. A randomized trial was conducted to assess the efficacy of daily (QD) or thrice weekly (TIW) administration of interferon-a (IFN) in high doses in combination with ribavirin (1.0‐1.2 g/day) in patients with chronic hepatitis C (CHC) who were nonresponders to previous IFN monotherapy. Interferon was administered as 10 MU IFN (QD or TIW) for 4 weeks, followed by 5 MU IFN (QD or TIW) for 20 weeks, and then by 3 MU IFN (QD or TIW) for 24 weeks. Sustained virological response (SVR) was evaluated in 142 patients who received at least one dose of medication. Onefourth of the patients achieved SVR, 26% of those treated with IFN QD and 25% of those treated with IFN TIW (P ¼ 0.85). For genotype 1 patients, SVR rates were 32.4 and 15.8% for IFN QD and IFN TIW, respectively, whereas for genotype non-1 patients the corresponding SVR rates were 20.6 and 36.4%, respectively (test of homogeneity: P ¼ 0.031). This finding was further confirmed by multivariate logistic regression analysis where a statistically significant interaction (P ¼ 0.012) was found between treatment and HCV genotype indicating that the IFN QD regimen was superior to IFN TIW among genotype 1 patients whereas, among genotype non-1 patients, the two treatments were similar (odds ratio of SVR in IFN QD vs IFN TIW: 3.33 among genotype 1 patients, 95% CI: 1.00‐ 11.14). In conclusion, re-treatment of patients not responding to previous IFN monotherapy with a combination of high daily dose of IFN with ribavirin may be beneficial for genotype 1 infected patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|